ABVX Valuation
Abivax SA
$
81.030
- Overview
- Forecast
- Valuation
- Earnings
ABVX Relative Valuation
ABVX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ABVX is overvalued; if below, it's undervalued.
Historical Valuation
Abivax SA (ABVX) is now in the Overvalued zone, suggesting that its current forward PS ratio of 324.73 is considered Overvalued compared with the five-year average of -6.96. The fair price of Abivax SA (ABVX) is between 9.87 to 39.16 according to relative valuation methord. Compared to the current price of 81.03 USD , Abivax SA is Overvalued By 106.9%.
Relative Value
Fair Zone
9.87-39.16
Current Price：81.03
106.9%
Overvalued
-24.65
PE
1Y
3Y
5Y
Trailing
Forward
-26.71
EV/EBITDA
Abivax SA. (ABVX) has a current EV/EBITDA of -26.71. The 5-year average EV/EBITDA is -12.22. The thresholds are as follows: Strongly Undervalued below -66.88, Undervalued between -66.88 and -39.55, Fairly Valued between 15.12 and -39.55, Overvalued between 15.12 and 42.45, and Strongly Overvalued above 42.45. The current Forward EV/EBITDA of -26.71 falls within the Historic Trend Line -Fairly Valued range.
-31.56
EV/EBIT
Abivax SA. (ABVX) has a current EV/EBIT of -31.56. The 5-year average EV/EBIT is -9.56. The thresholds are as follows: Strongly Undervalued below -66.52, Undervalued between -66.52 and -38.04, Fairly Valued between 18.93 and -38.04, Overvalued between 18.93 and 47.41, and Strongly Overvalued above 47.41. The current Forward EV/EBIT of -31.56 falls within the Historic Trend Line -Fairly Valued range.
324.73
PS
Abivax SA. (ABVX) has a current PS of 324.73. The 5-year average PS is 252.88. The thresholds are as follows: Strongly Undervalued below -1122.17, Undervalued between -1122.17 and -434.65, Fairly Valued between 940.40 and -434.65, Overvalued between 940.40 and 1627.93, and Strongly Overvalued above 1627.93. The current Forward PS of 324.73 falls within the Historic Trend Line -Fairly Valued range.
-47.22
P/OCF
Abivax SA. (ABVX) has a current P/OCF of -47.22. The 5-year average P/OCF is 1.76. The thresholds are as follows: Strongly Undervalued below -76.97, Undervalued between -76.97 and -37.61, Fairly Valued between 41.12 and -37.61, Overvalued between 41.12 and 80.49, and Strongly Overvalued above 80.49. The current Forward P/OCF of -47.22 falls within the Undervalued range.
-44.26
P/FCF
Abivax SA. (ABVX) has a current P/FCF of -44.26. The 5-year average P/FCF is 2.74. The thresholds are as follows: Strongly Undervalued below -110.10, Undervalued between -110.10 and -53.68, Fairly Valued between 59.16 and -53.68, Overvalued between 59.16 and 115.59, and Strongly Overvalued above 115.59. The current Forward P/FCF of -44.26 falls within the Historic Trend Line -Fairly Valued range.
Abivax SA (ABVX) has a current Price-to-Book (P/B) ratio of -667.22. Compared to its 3-year average P/B ratio of -18.52 , the current P/B ratio is approximately 3503.32% higher. Relative to its 5-year average P/B ratio of -3.71, the current P/B ratio is about 17890.38% higher. Abivax SA (ABVX) has a Forward Free Cash Flow (FCF) yield of approximately -2.95%. Compared to its 3-year average FCF yield of -20.31%, the current FCF yield is approximately -85.46% lower. Relative to its 5-year average FCF yield of -16.28% , the current FCF yield is about -81.86% lower.
-667.22
P/B
Median3y
-18.52
Median5y
-3.71
-2.95
FCF Yield
Median3y
-20.31
Median5y
-16.28
Competitors Valuation Multiple
The average P/S ratio for ABVX's competitors is 102.68, providing a benchmark for relative valuation. Abivax SA Corp (ABVX) exhibits a P/S ratio of 324.73, which is 216.26% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Performance Decomposition
1Y
3Y
5Y
Market capitalization of ABVX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of ABVX in the past 1 year is driven by Unknown.
People Also Watch
SENEA
Seneca Foods Corp
113.200
USD
+0.62%
JFIN
Jiayin Group Inc
12.580
USD
-4.55%
OLMA
Olema Pharmaceuticals Inc
5.460
USD
-1.09%
MLP
Maui Land & Pineapple Company Inc
17.380
USD
-0.23%
BWAY
Brainsway Ltd
15.560
USD
+1.43%
OABI
OmniAb Inc
1.600
USD
-2.44%
CRNT
Ceragon Networks Ltd
2.030
USD
+1.00%
BRY
Berry Corporation (Bry)
3.340
USD
+1.83%
SCM
Stellus Capital Investment Corp
14.530
USD
-0.34%
FAQ
Is Abivax SA (ABVX) currently overvalued or undervalued?
Abivax SA (ABVX) is now in the Overvalued zone, suggesting that its current forward PS ratio of 324.73 is considered Overvalued compared with the five-year average of -6.96. The fair price of Abivax SA (ABVX) is between 9.87 to 39.16 according to relative valuation methord. Compared to the current price of 81.03 USD , Abivax SA is Overvalued By 106.90% .
What is Abivax SA (ABVX) fair value?
How does ABVX's valuation metrics compare to the industry average?
What is the current P/B ratio for Abivax SA (ABVX) as of Sep 01 2025?
What is the current FCF Yield for Abivax SA (ABVX) as of Sep 01 2025?
What is the current Forward P/E ratio for Abivax SA (ABVX) as of Sep 01 2025?